Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical...

Related Keywords

New York ,United States ,Columbia University ,California ,New York Presbyterian Hospital ,Caelum Biosciences ,Suzanne Lentzsch ,Los Angeles ,Mike Moyer ,Ilya Rachman ,Gabriel Morris ,Company Contact ,Nasdaq ,Amyloidosis Program ,Astrazeneca ,Myeloma Steering Committee ,Lentzsch Co ,Immix Biopharma Inc ,Myeloma Working Group ,Nexcella Inc ,Steering Committee For The Society Of Hematology ,Scientific Committee For Plasma Cell Neoplasia ,Surgeons Of Columbia University ,Exchange Commission ,National Cancer Institute Myeloma Steering Committee ,Scientific Program Committee Hematologic Malignancies ,College Of Physicians ,Nexcella Scientific Advisory Board ,Associate Editor ,Clinical Oncology ,Nexcella Scientific Advisory ,Lentzsch Co Chairs ,Chief Financial Officer ,Immix Biopharma ,Clinical Medicine ,Multiple Myeloma ,Steering Committee ,Plasma Cell Neoplasia ,Career Development Committee ,International Myeloma Society ,Editorial Board ,Blood Cancer ,Tissue Specific Therapeutics ,Tissue Specific Therapeutic ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Risk Factor ,Annual Report ,Markets ,